Page 198 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg
P. 198
Chapter 7
Table 1. Baseline characteristics of patients from three original databases and of the combined database (total)
Characteristics
Sex, male
Age, median [range]
BSA, median [range]
Diagnosis
Rectum cancer
Anus cancer Vulva/vagina cancer
Pancreas cancer Upper GI cancer Other cancers
Grouped diagnosis
Pelvic region cancera Non-pelvic region cancerb
Other cancers
Treatment type
Capecitabine 5-FU
Treatment date [range]
Radiotherapy
Gy: median [range] Fr: median [range]
DPYD carriers total DPYD*2A
DPYD*13 c.2846A>T c.1236G>A
c.1236G>A homozygote
DB#1:NKI (N=495) N (%)
283 (57.2)
62 [32-86]
1.9 [1.38-2.71]
344 (69.5) 80 (16.2) 1 (0.2)
-
54 (10.9) 16 (3.2)
432 (87.3) 60 (12.1) 3 (0.6)
442 (89.3) 53 (10.7)
[01/2007- 02/2012]
50 [20-78]c 25 [5-39]c
36 (7.3) 7 (1.4) 1 (0.2) 9 (1.8) 17 (3.4) 2 (0.4)
DB#2:LUMC (N=240)
N (%)
122 (50.8)
65 [23-86]
1.89 [1.39-2.54]
157 (65.4) 36 (15.0) 17 (7.1)
5 (2.1)
10 (4.2) 15 (6.3)
223 (92.9) 17 (7.1)
-
183 (76.3) 57 (23.8)
[12/2012- 09/2017]
50 [7.2-69.4] 25 [4-38]
18 (7.5) 6 (2.5) -
-
12 (5) -
DB#3:CRO (N=93)
N (%)
60 (64.5)
63 [33-88] 1.85 [1.4-2.2]
93 (100) -
-
-
- -
93 (100) -
-
92 (98.9) 1 (1.1)
[04/2006- 04/2016]
55 [31.5-55.2] 25 [15-28]d
3 (3.2) -
-
1 (1.1) 2 (2.2) -
TOTAL (N=828) N (%)
465 (56.2)
63 [23-88]
1.9 [1.38-2.71]
594 (71.7) 116 (14) 18 (2.2)
5 (0.6)
64 (7.7) 31 (3.7)
748 (90.7) 77 (9.3)
3 (0.4)
717 (86.6) 111 (13.4)
[05/2006- 09/2017]
50 [7.2-78]c 25 [4-39]e
57 (6.9) 13 (1.6) 1 (0.1) 10 (1.2) 31 (3.7) 2 (0.2)
a Included are cancers of the colon sigmoidal, rectum, anus, vulva, vagina, cervix, uterus, endometrium, bladder, urethra, prostate and double tumours with one tumour in the pelvic area;
b Included are cancers of the breast, stomach, oesophagus, pancreas, skin, tongue;
c Seventy-one patients have missing data;
d One patient has missing data;
e Seventy-two patients have missing data.
Abbreviations: BSA: body surface area; CRO: Aviano National Cancer Institute; DB: database; DPYD: gene encoding dihydropyrimidine dehydrogenase; 5-FU: 5-fluorouracil; Fr: fractions; GI: gastro- intestinal tract; Gy: gray; LUMC: Leiden University Medical Center; NKI: Netherlands Cancer Institute.
196
